Combination BRAFV600E inhibition with the multitargeting tyrosine kinase inhibitor axitinib shows additive anticancer activity in BRAFV600E-mutant anaplastic thyroid cancer.

Viswanath Gunda,Chandrayee Ghosh,Jiangnan Hu,Lisa Zhang,Ya-Qin Zhang,Min Shen,Electron Kebebew

Thyroid : official journal of the American Thyroid Association（2023）

引用 0|浏览8

暂无评分

摘要

The novel combination of axitinib and BRAFV600E inhibition enhanced anticancer activity in in vitro and in vivo models of BRAFV600E-mutant ATC. This combination may have clinical utility in BRAFV600E-mutant ATC that is refractory to current standard therapy, namely combined BRAF and MEK inhibition.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要